- Home
- IRTC vs ACAD Comparison
IRTC vs ACAD Comparison
Compare IRTC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRTC
- ACAD
- Stock Information
- Founded
- IRTC 2006
- ACAD 1993
- Country
- IRTC United States
- ACAD United States
- Employees
- IRTC N/A
- ACAD N/A
- Industry
- IRTC Medical/Dental Instruments
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- IRTC Health Care
- ACAD Health Care
- Exchange
- IRTC Nasdaq
- ACAD Nasdaq
- Market Cap
- IRTC 3.1B
- ACAD 2.9B
- IPO Year
- IRTC 2016
- ACAD 2004
- Fundamental
- Price
- IRTC $103.70
- ACAD $17.20
- Analyst Decision
- IRTC Strong Buy
- ACAD Buy
- Analyst Count
- IRTC 10
- ACAD 19
- Target Price
- IRTC $120.20
- ACAD $25.33
- AVG Volume (30 Days)
- IRTC 542.3K
- ACAD 1.7M
- Earning Date
- IRTC 05-01-2025
- ACAD 05-07-2025
- Dividend Yield
- IRTC N/A
- ACAD N/A
- EPS Growth
- IRTC N/A
- ACAD N/A
- EPS
- IRTC N/A
- ACAD 1.36
- Revenue
- IRTC $591,839,000.00
- ACAD $957,797,000.00
- Revenue This Year
- IRTC $17.46
- ACAD $13.07
- Revenue Next Year
- IRTC $16.93
- ACAD $9.97
- P/E Ratio
- IRTC N/A
- ACAD $12.87
- Revenue Growth
- IRTC 20.13
- ACAD 31.85
- 52 Week Low
- IRTC $55.92
- ACAD $14.15
- 52 Week High
- IRTC $128.52
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- IRTC 47.47
- ACAD 40.10
- Support Level
- IRTC $97.02
- ACAD $16.59
- Resistance Level
- IRTC $106.00
- ACAD $17.70
- Average True Range (ATR)
- IRTC 5.34
- ACAD 0.77
- MACD
- IRTC -1.00
- ACAD -0.19
- Stochastic Oscillator
- IRTC 36.38
- ACAD 15.14
About IRTC iRhythm Technologies Inc.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.